The lower endometrial cancer risks for those diagnosed with BC after 2009 may also be partly due to an increase in aromatase inhibitor usage in BC treatment in later years, which is associated with a lower endometrial SPC risk than tamoxifen29 but a similar decrease in risk was observed in our data among those did not receive hormonal therapy. Here, CYP19A1 is linked to breast cancer.